ArticleArchives of sexual behavior2020
Trajectories of Adolescents Treated with Gonadotropin-Releasing Hormone Analogues for Gender Dysphoria.
Article in Archives of sexual behavior, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 107 citations in OpenAlex.
- Endocrine Management of Transgender and Gender-Diverse Adolescents: Expert Opinion of the ESPE Working Group on Gender Incongruence and the Endo-ERN Main Thematic Group on Sexual Development and Maturation.Hormone research in paediatrics · 2026Guideline
- Systematic Review: Puberty suppression with GnRH analogues in adolescents with gender incongruity.Journal of endocrinological investigation · 2021Pooled it
- Association of GnRH agonists with depression and suicide/self-injury: a FAERS pharmacovigilance study.Endocrine connections · 2026Article
- Long-term testicular changes caused by the temporary suspension of puberty initiated at different stages of development.Frontiers in cell and developmental biology · 2026Article
- The Cass Review and Gender-Related Care for Young People in Canada: A Commentary on the Canadian Paediatric Society Position Statement on Transgender and Gender-Diverse Youth.Archives of sexual behavior · 2025Article
- GnRH analogs as a monotherapy in transgender and gender-diverse adolescents: clinical insights from a single-center study.Endocrine connections · 2025Article
- Psychological and Physical Health Outcomes Associated with Gender-Affirming Medical Care for Transgender and Gender-Diverse Youth: A Critical Review.Healthcare (Basel, Switzerland) · 2025Review
- The Cass Review: Cis-supremacy in the UK's approach to healthcare for trans children.International journal of transgender health · 2025Article
- Co-design and usability of an interactive web-based fertility decision aid for transgender youth and young adults.Journal of pediatric psychology · 2025Article
- Supporting autonomy in young people with gender dysphoria: psychotherapy is not conversion therapy.Journal of medical ethics · 2024Article
- Clinical profiles and care of transgender children and adolescents who receive specialized consultations: do individuals who are assigned female at birth differ?Child and adolescent psychiatry and mental health · 2024Article
- Another Myth of Persistence?Archives of sexual behavior · 2024Article
- Growth and Adult Height Attainment in Danish Transgender Adolescents Treated With GnRH Analog and Sex Hormones.The Journal of clinical endocrinology and metabolism · 2024Observational
- Gender Reassignment and the Role of the Laboratory in Monitoring Gender-Affirming Hormone Therapy.Journal of clinical medicine · 2024Review
- Psychodynamic psychotherapy for gender dysphoria is not conversion therapy.Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent · 2024Article
- Adolescent neurocognitive development and decision-making abilities regarding gender-affirming care.Developmental cognitive neuroscience · 2024Review
- Gender Affirming Hormone Treatment for Trans Adolescents: A Four Principles Analysis.Journal of bioethical inquiry · 2024Article
- Puberty Suppression for Pediatric Gender Dysphoria and the Child's Right to an Open Future.Archives of sexual behavior · 2024Article
- Trajectories of Gender Identity and Depressive Symptoms in Youths.JAMA network open · 2024Article
- Recognizing and responding to misleading trans health research.International journal of transgender health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gonadotropin-releasing hormone analogues (GnRHa) are recommended as initial treatment for adolescents diagnosed with gender dysphoria, providing time to follow gender identity development and consider further treatment wishes without distress caused by unwanted pubertal changes. This has been described as an extended diagnostic phase. However, there are also concerns about the physical, neurocognitive, and psychosocial effects of this treatment. In this retrospective study, we document trajectories after the initiation of GnRHa and explore reasons for extended use and discontinuation of GnRHa. Treatment was considered appropriate in 143 (67%) of the 214 adolescents eligible for GnRHa treatment by virtue of their age/pubertal status, and all started GnRHa (38 transgirls, 105 transboys; median age, 15.0 years [range, 11.1-18.6] and 16.1 years [range, 10.1-17.9]). After a median duration of 0.8 years (0.3-3.8) on GnRHa, 125 (87%) started gender-affirming hormones (GAH). Nine (6%) discontinued GnRHa, five of whom no longer wished gender-affirming treatment. Thirteen had used GnRHa for longer than required by protocol for reasons other than logistics and regularly met with a mental health professional during this time, supporting the use of GnRHa treatment as an extended diagnostic phase. In conclusion, the vast majority who started GnRHa proceeded to GAH, possibly due to eligibility criteria that select those highly likely to pursue further gender-affirming treatment. Due to the observational character of the study, it is not possible to say if GnRHa treatment itself influenced the outcome. Few individuals discontinued GnRHa, and only 3.5% no longer wished gender-affirming treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.